AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20661160 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval Training (IT)
Number of subjects: 21
Study 20661160 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 21
Study 19309331 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD in the proband
Number of subjects: 123
Study 19309331 — intervention group
Group type: EXPERIMENTAL
Intervention: PSUD in the proband
Number of subjects: 123
Study 19309331 — intervention group
Group type: COMPARATOR
Intervention: ADHD and PSUD in probands
Number of subjects: 123
Study 17688011 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched Intervention (EI)
Number of subjects: 1553
Study 17688011 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 1553
Study 15906019 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol-HCl 100 mg
Number of subjects: 26
Study 15906019 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol-HCl 150 mg
Number of subjects: 26
Study 15906019 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol-HCl 50 mg
Number of subjects: 26
Study 15906019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 12270852 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitaxsentan (selective ET(A) receptor antagonist) infused at increasing rates (0.3125 to 10 mg/min) in patients with HF
Number of subjects: 12
Study 12270852 — intervention group
Group type: COMPARATOR
Intervention: Sitaxsentan (selective ET(A) receptor antagonist) infused in control subjects
Number of subjects: 12
Study 9638665 — intervention group
Group type: EXPERIMENTAL
Intervention: Various chemotherapy protocols (SIOP 1, SIOP 2, HDMTX/VCR, HIT protocol 89/91, Carbo-PEI)
Number of subjects: 46
Study 9638665 — intervention group
Group type: EXPERIMENTAL
Intervention: HIT protocol 89/91 as first-line treatment
Number of subjects: 46
Study 9638665 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (surgery and radiotherapy alone)
Number of subjects: 46
Study 7990463 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental expectancy modification condition (10-minute video intervention)
Number of subjects: 268
Study 7990463 — intervention group
Group type: COMPARATOR
Intervention: Control condition (10-minute video presenting facts about alcohol's deleterious effects)
Number of subjects: 268
Study 7990463 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control condition
Number of subjects: 268
Study 2538960 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery + Radiation
Number of subjects: 71
Study 2538960 — intervention group
Group type: COMPARATOR
Intervention: Radiation
Number of subjects: 71
Study 30018166 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention using quality improvement and chronic care model approaches to improve delivery of penicillin prophylaxis
Number of subjects: 0
Study 30018166 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative evaluation through interviews and observations
Number of subjects: 0
Study 30018166 — intervention group
Group type: EXPERIMENTAL
Intervention: Action items developed by clinic staff with project officers
Number of subjects: 0
Study 30018166 — intervention group
Group type: EXPERIMENTAL
Intervention: Later stages of the study
Number of subjects: 0
Study 27447160 — intervention group
Group type: EXPERIMENTAL
Intervention: Test implant system
Number of subjects: 120
Study 27447160 — intervention group
Group type: COMPARATOR
Intervention: Predicate implant system
Number of subjects: 120
Study 25197812 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bolus of normal saline (22 mL/kg body weight) after sleep onset with compression stockings to prevent fluid accumulation in the legs.
Number of subjects: 17
Study 25197812 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infusion to keep the vein open (control arm).
Number of subjects: 17
Study 24373251 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI3-bevacizumab
Number of subjects: 61
Study 20961386 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine gel (CHX-Gel)
Number of subjects: 0
Study 20961386 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine mouthwash (CHX-MW)
Number of subjects: 0
Study 20961386 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine dentifrice-gel (CHX-DFG)
Number of subjects: 0
Study 20961386 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular dentifrice (RDF)
Number of subjects: 0
Study 20961386 — intervention group
Group type: COMPARATOR
Intervention: CHX-DFG and RDF
Number of subjects: 0
Study 20961386 — intervention group
Group type: COMPARATOR
Intervention: 1% CHX-Gel and 0.2% CHX-MW
Number of subjects: 0
Study 18381138 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 1404
Study 18381138 — intervention group
Group type: COMPARATOR
Intervention: Beta-blockers
Number of subjects: 1404
Study 18381138 — intervention group
Group type: COMPARATOR
Intervention: Antiplatelet drugs
Number of subjects: 1404
Study 18381138 — intervention group
Group type: COMPARATOR
Intervention: Statin use, beta-blockers, antiplatelet drugs
Number of subjects: 1404
Study 16763088 — intervention group
Group type: EXPERIMENTAL
Intervention: Transbond Plus Self‐Etching Primer (SEP)
Number of subjects: 39
Study 16763088 — intervention group
Group type: COMPARATOR
Intervention: Conventional separate two‐step etch and primer system
Number of subjects: 39
Study 14567873 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated feedback system comments on non-adherence to guidelines
Number of subjects: 24
Study 11295903 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 81)
Number of subjects: 117
Study 11295903 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 36)
Number of subjects: 117
Study 9140517 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific immunotherapy with standardized extracts of Dermatophagoides pteronyssinus and D. farinae
Number of subjects: 30
Study 9140517 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 30
Study 8186117 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryosurgery
Number of subjects: 0
Study 8186117 — intervention group
Group type: COMPARATOR
Intervention: Intralesional triamcinolone
Number of subjects: 0
Study 2884454 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg 33B3.1 daily by intravenous infusion for 14 days (group A)
Number of subjects: 27
Study 2884454 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg 33B3.1 daily by intravenous infusion for 14 days (group B)
Number of subjects: 27
Study 2884454 — intervention group
Group type: COMPARATOR
Intervention: Historical control patients (prednisone/azathioprine)
Number of subjects: 27
Study 2884454 — intervention group
Group type: COMPARATOR
Intervention: Patients previously treated with ATG
Number of subjects: 27
Study 31707498 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol lotion
Number of subjects: 42
Study 31707498 — intervention group
Group type: EXPERIMENTAL
Intervention: Squill extract
Number of subjects: 42
Study 29616028 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-acting antiviral (DAA) drug therapies
Number of subjects: 31
Study 29616028 — intervention group
Group type: COMPARATOR
Intervention: Chronic HCV infection
Number of subjects: 31
Study 29616028 — intervention group
Group type: COMPARATOR
Intervention: HCV clearance by DAA drug therapy
Number of subjects: 31
Study 28931439 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body vibration (WBV) exercise for 12 weeks
Number of subjects: 180
Study 28931439 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower extremity resistance training for 12 weeks
Number of subjects: 180
Study 28931439 — intervention group
Group type: COMPARATOR
Intervention: Health education for 12 weeks
Number of subjects: 180
Study 25285994 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral supplement containing Phyllanthus emblica (100 mg), vitamin E (10 mg), and carotenoids (4.7 mg) three times/day for 6 months
Number of subjects: 65
Study 25285994 — intervention group
Group type: COMPARATOR
Intervention: Control group (not treated with antioxidants)
Number of subjects: 65
Study 23222000 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher leptin levels (T3 vs T1)
Number of subjects: 15
Study 23222000 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher leptin levels (T3 vs T1) after adjustment for BMI
Number of subjects: 15
Study 23222000 — intervention group
Group type: COMPARATOR
Intervention: Adiponectin and HMW adiponectin
Number of subjects: 15
Study 22081178 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir plus prednisolone
Number of subjects: 68
Study 22081178 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone alone
Number of subjects: 68
Study 18457936 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin three-times-daily (TD)
Number of subjects: 155
Study 18457936 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxithromycin once-daily (OD)
Number of subjects: 155
Study 18457936 — intervention group
Group type: COMPARATOR
Intervention: Placebo once-daily (OD)
Number of subjects: 155
Study 18457936 — intervention group
Group type: COMPARATOR
Intervention: Placebo three-times-daily (TD)
Number of subjects: 155
Study 16935049 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive exercise program (9-month standardized home-based program starting 3 months after surgery)
Number of subjects: 39
Study 16935049 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy (PT)
Number of subjects: 39
Study 12891825 — intervention group
Group type: EXPERIMENTAL
Intervention: Red palm oil supplementation (2,400 micrograms of beta-carotene)
Number of subjects: 170
Study 12891825 — intervention group
Group type: COMPARATOR
Intervention: Groundnut oil (control)
Number of subjects: 170
Study 12891825 — intervention group
Group type: EXPERIMENTAL
Intervention: Red palm oil supplementation
Number of subjects: 170
Study 10849375 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 28
Study 10849375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 9440634 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrin-17 (15 pmol/kg/hr)
Number of subjects: 9
Study 9440634 — intervention group
Group type: COMPARATOR
Intervention: Control (saline infusion)
Number of subjects: 9
Study 29633652 — intervention group
Group type: EXPERIMENTAL
Intervention: Music Therapy Group (MTG) - 10 individual sessions of music therapy (30-40 minutes each) with a trained music therapist.
Number of subjects: 116
Study 29633652 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - standard care without music therapy.
Number of subjects: 116
Study 27793197 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered acupressure intervention
Number of subjects: 200
Study 27793197 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 200
Study 25285887 — intervention group
Group type: EXPERIMENTAL
Intervention: Tat1-86 (25 μg)
Number of subjects: 0
Study 25285887 — intervention group
Group type: EXPERIMENTAL
Intervention: gp120 (100 ng)
Number of subjects: 0
Study 25285887 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 0
Study 23213977 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint application during the dog days and the three nine-day periods after the winter solstice (group A)
Number of subjects: 152
Study 23213977 — intervention group
Group type: COMPARATOR
Intervention: Acupoint application during the dog days only (group B)
Number of subjects: 152
Study 19694216 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/d) for 3 months
Number of subjects: 30
Study 16796606 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion (steady-state concentration of 100 mU L(-1))
Number of subjects: 9
Study 16796606 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 9
Study 16796606 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion
Number of subjects: 9
Study 15200183 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 40
Study 15200183 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 40
Study 11389245 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual pump (MP; Avent ISIS)
Number of subjects: 145
Study 11389245 — intervention group
Group type: COMPARATOR
Intervention: Electric pump (EP; Egnell)
Number of subjects: 145
Study 9227168 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid (triamcinolone acetonide, TA) injection
Number of subjects: 16
Study 9227168 — intervention group
Group type: EXPERIMENTAL
Intervention: Yttrium-90 plus corticosteroid (TA+Y) injection
Number of subjects: 16
Study 8215545 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (400-800 micrograms/day)
Number of subjects: 40
Study 8215545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8215545 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 40
Study 3632371 — intervention group
Group type: EXPERIMENTAL
Intervention: CR-5 (controlled release levodopa-carbidopa)
Number of subjects: 15
Study 3632371 — intervention group
Group type: COMPARATOR
Intervention: Sinemet (levodopa-carbidopa)
Number of subjects: 15
Study 28898536 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxegol 12.5 mg
Number of subjects: 1352
Study 28898536 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxegol 25 mg
Number of subjects: 1352
Study 28898536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1352
Study 27396361 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-Water Immersion (CWI)
Number of subjects: 10
Study 27396361 — intervention group
Group type: COMPARATOR
Intervention: Whole-Body Cryotherapy (WBC)
Number of subjects: 10
Study 26135351 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg crystalline vitamin B‐12 daily for 12 months
Number of subjects: 201
Study 26135351 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 201
Study 23096251 — intervention group
Group type: EXPERIMENTAL
Intervention: Ospemifene 30 mg/day
Number of subjects: 180
Study 23096251 — intervention group
Group type: EXPERIMENTAL
Intervention: Ospemifene 60 mg/day
Number of subjects: 180
Study 23096251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 20962160 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-fortified biscuits (20 mg Fe/d, 4 times/week)
Number of subjects: 139
Study 20962160 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-fortified biscuits
Number of subjects: 139
Study 20962160 — intervention group
Group type: COMPARATOR
Intervention: Non-fortified biscuits
Number of subjects: 139
Study 18785059 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO‐E solution (6% carbohydrate, 50 mg Na/500 ml)
Number of subjects: 10
Study 18785059 — intervention group
Group type: COMPARATOR
Intervention: Placebo (non‐CHO‐E)
Number of subjects: 10
Study 18785059 — intervention group
Group type: COMPARATOR
Intervention: No fluid
Number of subjects: 10
Study 16598386 — intervention group
Group type: COMPARATOR
Intervention: Topical metronidazole (Noritate 1% Cream, MetroCream 0.75% Cream, MetroLotion 0.75% Lotion, Metrogel 0.75% and 1% Topical Gel)
Number of subjects: 0
Study 12769218 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermabond closure (TA)
Number of subjects: 46
Study 12769218 — intervention group
Group type: COMPARATOR
Intervention: Subcuticular closure (SC)
Number of subjects: 46
Study 10671842 — intervention group
Group type: EXPERIMENTAL
Intervention: Needleless injector (J-Tip)
Number of subjects: 72
Study 10671842 — intervention group
Group type: COMPARATOR
Intervention: Conventional syringe and 25 G needle
Number of subjects: 72
Study 9323734 — intervention group
Group type: EXPERIMENTAL
Intervention: Acuvue lenses with UV blocker
Number of subjects: 94
Study 9323734 — intervention group
Group type: COMPARATOR
Intervention: Conventional Acuvue lenses without UV blocker
Number of subjects: 94
Study 8222891 — intervention group
Group type: EXPERIMENTAL
Intervention: Andriol
Number of subjects: 62
Study 8222891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 3094139 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin 500/500 mg q6h (77 patients, 56 evaluable for efficacy)
Number of subjects: 163
Study 3094139 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin 1.5 mg/kg plus clindamycin 600 mg q6h (86 patients, 62 evaluable for efficacy)
Number of subjects: 163
Study 30508538 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual high-dose liquid birch pollen extract (40,000 AUN/mL)
Number of subjects: 406
Study 28699560 — intervention group
Group type: EXPERIMENTAL
Intervention: Community mobilisation for dengue prevention (specific details not provided)
Number of subjects: 55723
Study 25668402 — intervention group
Group type: EXPERIMENTAL
Intervention: LHTLH (live high-train low in hypoxia)
Number of subjects: 32
Study 25668402 — intervention group
Group type: EXPERIMENTAL
Intervention: LHTL (live high-train low in normoxia)
Number of subjects: 32
Study 25668402 — intervention group
Group type: COMPARATOR
Intervention: LLTL (live low-train low)
Number of subjects: 32
Study 25668402 — intervention group
Group type: EXPERIMENTAL
Intervention: Both hypoxic groups (LHTLH and LHTL)
Number of subjects: 32
Study 25668402 — intervention group
Group type: EXPERIMENTAL
Intervention: LHTLH
Number of subjects: 32
Study 25668402 — intervention group
Group type: EXPERIMENTAL
Intervention: LHTL
Number of subjects: 32
Study 25668402 — intervention group
Group type: COMPARATOR
Intervention: LLTL
Number of subjects: 32
Study 25668402 — intervention group
Group type: EXPERIMENTAL
Intervention: LHTLH and LHTL
Number of subjects: 32
Study 23480673 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based progressive resistance training (N=26)
Number of subjects: 50
Study 23480673 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation (N=24)
Number of subjects: 50
Study 22159775 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical Nutrition Therapy (MNT)
Number of subjects: 147
Study 22159775 — intervention group
Group type: COMPARATOR
Intervention: Control group (nutrition information at enrollment)
Number of subjects: 147
Study 18839644 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral thiocolchicoside (TC) for one week
Number of subjects: 60
Study 18839644 — intervention group
Group type: COMPARATOR
Intervention: Adrenergic alpha 2 agonist tizanidine (TZ) for one week
Number of subjects: 60
Study 18839644 — intervention group
Group type: COMPARATOR
Intervention: Comparison of TC and TZ
Number of subjects: 60
Study 16863605 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (PCI)
Number of subjects: 102
Study 16863605 — intervention group
Group type: COMPARATOR
Intervention: Conservative therapy
Number of subjects: 102
Study 15159538 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine fortification
Number of subjects: 0
Study 11294048 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 16 mg
Number of subjects: 200
Study 11294048 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg
Number of subjects: 200
Study 11294048 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 16 mg and Lisinopril 20 mg (combination treatment)
Number of subjects: 200
Study 9272261 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 3 x 20 mg/day
Number of subjects: 67
Study 9272261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 7688008 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimipramine
Number of subjects: 37
Study 7688008 — intervention group
Group type: COMPARATOR
Intervention: Doxepin
Number of subjects: 37
Study 3563441 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients classified as 'good'
Number of subjects: 60
Study 3563441 — intervention group
Group type: COMPARATOR
Intervention: Patients classified as 'bad'
Number of subjects: 60
Study 30845044 — intervention group
Group type: EXPERIMENTAL
Intervention: Ottawa Surgical Competency Operating Room Evaluation (O-Score) assessments
Number of subjects: 294
Study 30845044 — intervention group
Group type: EXPERIMENTAL
Intervention: P-score evaluations
Number of subjects: 294
Study 30845044 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined OP-score instrument (modified O-score and P-score)
Number of subjects: 294
Study 27080737 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium (n = 37)
Number of subjects: 103
Study 27080737 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin, n = 47)
Number of subjects: 103
Study 25920634 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte-poor (type-4B) PRP injection
Number of subjects: 25
Study 25920634 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine injection
Number of subjects: 25
Study 24029010 — intervention group
Group type: EXPERIMENTAL
Intervention: Action observation training
Number of subjects: 30
Study 24029010 — intervention group
Group type: COMPARATOR
Intervention: Motor imagery training
Number of subjects: 30
Study 21193183 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma exposure and PTSD assessment
Number of subjects: 110
Study 21193183 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD presence
Number of subjects: 110
Study 19684043 — intervention group
Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa (150 microg single injection)
Number of subjects: 1506
Study 19684043 — intervention group
Group type: COMPARATOR
Intervention: Recombinant FSH (200 IU daily injections)
Number of subjects: 1506
Study 19684043 — intervention group
Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa
Number of subjects: 1506
Study 19684043 — intervention group
Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa and rFSH
Number of subjects: 1506
Study 18405128 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance (IGT)
Number of subjects: 1659
Study 18405128 — intervention group
Group type: EXPERIMENTAL
Intervention: Early glucose intolerance (EGI)
Number of subjects: 1659
Study 18405128 — intervention group
Group type: COMPARATOR
Intervention: Normal glucose tolerance (NGT)
Number of subjects: 1659
Study 18405128 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin resistance (IR)
Number of subjects: 1659
Study 18405128 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulinogenic index
Number of subjects: 1659
Study 18405128 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival time free from diabetes
Number of subjects: 1659